Although it is estimated that COVID-19 life-threatening conditions may be diagnosed in less than 1:1000 infected individuals below the age of 50, but the real impact of this pandemic on pediatric patients with different types of primary immunodeficiency (PID) is not elucidated. The current prospective study on a national registry of PID patients showed that with only 1.23 folds higher incidence of infections, these patients present a 10-folds higher mortality rate compared to population mainly in patients with combined immunodeficiency and immune dysregulation. Therefore, further management modalities against COVID-19 should be considered to improve the survival rate in these two PID entities using hematopoietic stem cell transplantation and immunomodulatory agents. Supplementary Information The online version contains supplementary material available at 10.1007/s10875-020-00928-x.
【저자키워드】 COVID-19, Primary Immunodeficiency, mortality rate, Severe viral infection, 【초록키워드】 pandemic, Prospective Study, immunodeficiency, infections, management, Patient, age, survival rate, incidence, Immunomodulatory agents, combined immunodeficiency, immune dysregulation, Stem cell transplantation, Pediatric patient, supplementary material, infected individual, life-threatening, National, IMPROVE, diagnosed, condition, less, PID, 【제목키워드】 SARS-CoV-2, Impact,